Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.
Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Antibody developer Kymab Ltd has instated Sonia Quaratino as its first Chief Medical Officer. She will manage the clinical development of the Group’s expanding therapeutic antibody portfolio.
Biopharmaceutical company Oryzon Genomics has named Roger Bullock its Chief Medical Officer. He will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company.
London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.
The European biotech industry association EuropaBio has named John Brennan as its new Secretary General. The life sciences expert will take over his new position in June.
In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
Following the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer before.